Efficiency of Chitosan-Coated PLGA Nanocarriers for Cellular Delivery of siRNA and CRISPR/Cas9 Complex

  title={Efficiency of Chitosan-Coated PLGA Nanocarriers for Cellular Delivery of siRNA and CRISPR/Cas9 Complex},
  author={Ashu Srivastav and Kritika Gupta and Debojyoti Chakraborty and Prajakta P Dandekar and Ratnesh D Jain},
  journal={Journal of Pharmaceutical Innovation},
Purpose Most studies based on siRNA or CRISPR/Cas9 systems rely on viral vectors for their transfection. However, these viral vectors are immunogenic, which limits their application in gene therapy. Thus, identification of novel vectors with higher safety and improved targeting is desirable. Hence, we have explored the potential of biodegradable, chitosan coated PLGA nanocarriers for intracellular delivery of CRISPR/Cas9, and siRNA. In this investigation, we have compared the efficiency of… 

A Short Review on Recent Applications of Chitosan Biopolymer in Gene and Drug Delivery

The amenability of structural modification, non-toxicity and high biodegradability of chitosan derivatives can make them prospective carriers for controlled drug delivery in future.

Advances in Chitosan-Based CRISPR/Cas9 Delivery Systems

A critical analysis of the different approaches for the generation of chitosan-based CRISPR/Cas9 delivery systems and suggestions for future developments are offered.



Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.

  • H. RagelleR. Riva V. Préat
  • Biology
    Journal of controlled release : official journal of the Controlled Release Society
  • 2014

PEGylated Chitosan for Nonviral Aerosol and Mucosal Delivery of the CRISPR/Cas9 System in Vitro.

The basis for the delivery of a gene-editing system by PEGylated chitosan nanocomplexes is established and showed the capability to protect loaded nucleic acids from DNase I digestion and from the stresses of nebulization.

Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures.

PLGA nanoparticles in drug delivery: the state of the art.

The crux of the problem is the stability of nanoparticles after preparation, which is being addressed by freeze-drying using different classes of lyoprotectants.

Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing

A generalizable methodology is reported that allows engineering of modified lipid nanoparticles to efficiently deliver RNPs into cells and edit tissues including muscle, brain, liver, and lungs to facilitate broad nanoparticle development for a variety of disease targets amenable to protein delivery and precise gene correction approaches.

Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA.

It is shown that ZNP delivery of sgRNA enables permanent DNA editing with an indefinitely sustained 95 % decrease in protein expression, and represents a promising step towards improving the safety and utility of gene editing.

Recent advances in PLGA particulate systems for drug delivery

This review focuses on novel and innovative PLGA-based particulate drug delivery carriers in recent years.

CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation

A microfluidic membrane deformation method is introduced to deliver sgRNA and Cas9 into different cell types and achieve successful genome editing and could potentially enable new avenues of biomedical research and gene targeting therapy such as mutation correction of disease genes through combination of the CRISPR-Cas9–mediated knockin system.

CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.

The rapidly developing CRISPR/Cas9-based technologies for disease modeling and gene correction and recent progress toward Cas9/guide RNA (gRNA) delivery based on viral and nonviral vectors are reviewed.